Advertisement

International Orthopaedics

, Volume 36, Issue 11, pp 2315–2321 | Cite as

Role of vascular endothelial growth factor as a tumour marker in osteosarcoma: a prospective study

  • Shishir Rastogi
  • Ramakant Kumar
  • Sukesh Rao Sankineani
  • Kanniraj Marimuthu
  • Laxman Rijal
  • Shyam Prakash
  • Divesh Jalan
  • Shah Alam Khan
  • Mehar C. Sharma
Original Paper

Abstract

Purpose

A prospective study was undertaken to evaluate the diagnostic and prognostic significance of serum levels of vascular endothelial growth factor (VEGF) in patients with primary localised osteosarcoma.

Methods

Serum VEGF levels were measured by an enzyme-linked immunosorbent assay (ELISA) in blood samples collected prechemotherapy, postchemotherapy, and postsurgery in 40 patients with histologically proven primary osteosarcoma. Comparison was made between serum VEGF level of healthy controls (n = 10) and prechemotherapy patient sera to evaluate its diagnostic potential. Serum VEGF levels of patients with and without metastasis were compared. Immunohistochemical staining was done to establish the correlation between serum and tissue VEGF expression. The Kaplan–Meier curve was used for survival analysis

Results

No significant relationship was observed between serum VEGF levels and age, gender, tumour size, local recurrence or histopathological subtypes of osteosarcoma. We observed significantly raised mean serum VEGF in patient sera compared with healthy controls (p = 0.001). Significant fall in mean serum VEGF level was observed following chemotherapy (p = 0.001). Patients who developed metastases had significantly higher serum VEGF levels compared with the nonmetastatic group (P = 0.001). Serum VEGF levels correlated well with VEGF expression in tissues.

Conclusion

Serum VEGF levels might prove to be of diagnostic, predictive and prognostic value in patients with primary osteosarcoma, although further studies with larger sample size and longer follow-up is needed to support the hypothesis.

Keywords

Vascular Endothelial Growth Factor Osteosarcoma Pulmonary Metastasis Vascular Endothelial Growth Factor Expression Vascular Endothelial Growth Factor Level 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgments

The authors have not received any fund or grant from any professional body or institution. We thank Dr. Shyam Prakash for helping in laboratory analysis of the serum samples. We also thank Mr. Guresh Kumar for statistical support.

Conflict of interest

The authors declare no conflict of interest.

References

  1. 1.
    Picci P, Mercuri M, Ferrari S, Alberghini M, Briccoli A, Ferrari C et al (2010) Survival in high-grade osteosarcoma: improvement over 21 years at a single institution. Ann Oncol 21(6):1366–1373PubMedCrossRefGoogle Scholar
  2. 2.
    Trueta J, Amato VP (1960) The vascular contribution to osteogenesis. III. Changes in the growth cartilage caused by experimentally induced ischaemia. J Bone Joint Surg Br 42-B:571–587PubMedGoogle Scholar
  3. 3.
    Hicklin DJ, Ellis LM (2005) Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23(5):1011–1027PubMedCrossRefGoogle Scholar
  4. 4.
    Kaya M, Wada T, Kawaguchi S, Nagoya S, Yamashita T, Abe Y et al (2002) Increased pre-therapeutic serum vascular endothelial growth factor in patients with early clinical relapse of osteosarcoma. Br J Cancer 86(6):864–869PubMedCrossRefGoogle Scholar
  5. 5.
    Takahashi Y, Tucker SL, Kitadai Y, Koura AN, Bucana CD, Cleary KR et al (1997) Vessel counts and expression of vascular endothelial growth factor as prognostic factors in node-negative colon cancer. Arch Surg 132(5):541–546PubMedCrossRefGoogle Scholar
  6. 6.
    Linderholm B, Tavelin B, Grankvist K, Henriksson R (1998) Vascular endothelial growth factor is of high prognostic value in node-negative breast carcinoma. J Clin Oncol 16(9):3121–3128PubMedGoogle Scholar
  7. 7.
    Imoto H, Osaki T, Taga S, Ohgami A, Ichiyoshi Y, Yasumoto K (1998) Vascular endothelial growth factor expression in non-small-cell lung cancer: prognostic significance in squamous cell carcinoma. J Thorac Cardiovasc Surg 115(5):1007–1014PubMedCrossRefGoogle Scholar
  8. 8.
    Saito H, Tsujitani S, Kondo A, Ikeguchi M, Maeta M, Kaibara N (1999) Expression of vascular endothelial growth factor correlates with hematogenous recurrence in gastric carcinoma. Surgery 125(2):195–201PubMedCrossRefGoogle Scholar
  9. 9.
    Smith BD, Smith GL, Carter D, Sasaki CT, Haffty BG (2000) Prognostic significance of vascular endothelial growth factor protein levels in oral and oropharyngeal squamous cell carcinoma. J Clin Oncol 18(10):2046–2052PubMedGoogle Scholar
  10. 10.
    Poon RT, Fan ST, Wong J (2001) Clinical implications of circulating angiogenic factors in cancer patients. J Clin Oncol 19(4):1207–1225PubMedGoogle Scholar
  11. 11.
    Miyake H, Hara I, Yamanaka K, Gohji K, Arakawa S, Kamidono S (1999) Elevation of serum level of vascular endothelial growth factor as a new predictor of recurrence and disease progression in patients with superficial urothelial cancer. Urology 53(2):302–307PubMedCrossRefGoogle Scholar
  12. 12.
    Werther K, Christensen IJ, Nielsen HJ (2002) Prognostic impact of matched preoperative plasma and serum VEGF in patients with primary colorectal carcinoma. Br J Cancer 86(3):417–423PubMedCrossRefGoogle Scholar
  13. 13.
    Circulating VEGF levels in the serum of gastric can… [Ann Surg. 2002]—PubMed—NCBI [Internet]. [cited 2012 Jan 2]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12131083
  14. 14.
    Teknos TN, Cox C, Yoo S, Chepeha DB, Wolf GT, Bradford CR et al (2002) Elevated serum vascular endothelial growth factor and decreased survival in advanced laryngeal carcinoma. Head Neck 24(11):1004–1011PubMedCrossRefGoogle Scholar
  15. 15.
    Cooper BC, Ritchie JM, Broghammer CLW, Coffin J, Sorosky JI, Buller RE et al (2002) Preoperative serum vascular endothelial growth factor levels: significance in ovarian cancer. Clin Cancer Res 8(10):3193–3197PubMedGoogle Scholar
  16. 16.
    Poon RTP, Ho JWY, Tong CSW, Lau C, Ng IOL, Fan S-T (2004) Prognostic significance of serum vascular endothelial growth factor and endostatin in patients with hepatocellular carcinoma. Br J Surg 91(10):1354–1360PubMedCrossRefGoogle Scholar
  17. 17.
    Kaya M, Wada T, Akatsuka T, Kawaguchi S, Nagoya S, Shindoh M et al (2000) Vascular endothelial growth factor expression in untreated osteosarcoma is predictive of pulmonary metastasis and poor prognosis. Clin Cancer Res 6(2):572–577PubMedGoogle Scholar
  18. 18.
    Lee YH, Tokunaga T, Oshika Y, Suto R, Yanagisawa K, Tomisawa M et al (1999) Cell-retained isoforms of vascular endothelial growth factor (VEGF) are correlated with poor prognosis in osteosarcoma. Eur J Cancer 35(7):1089–1093PubMedCrossRefGoogle Scholar
  19. 19.
    Holzer G, Obermair A, Koschat M, Preyer O, Kotz R, Trieb K (2001) Concentration of vascular endothelial growth factor (VEGF) in the serum of patients with malignant bone tumors. Med Pediatr Oncol 36(6):601–604PubMedCrossRefGoogle Scholar
  20. 20.
    Rutkowski P, Kamińska J, Kowalska M, Ruka W, Steffen J (2003) Cytokine and cytokine receptor serum levels in adult bone sarcoma patients: correlations with local tumor extent and prognosis. J Surg Oncol 84(3):151–159PubMedCrossRefGoogle Scholar
  21. 21.
    Kaya M, Wada T, Nagoya S, Sasaki M, Matsumura T, Yamashita T (2009) The level of vascular endothelial growth factor as a predictor of a poor prognosis in osteosarcoma. J Bone Joint Surg Br 91(6):784–788PubMedCrossRefGoogle Scholar
  22. 22.
    Stacker SA, Caesar C, Baldwin ME, Thornton GE, Williams RA, Prevo R et al (2001) VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nat Med 7(2):186–191PubMedCrossRefGoogle Scholar
  23. 23.
    Skobe M, Hawighorst T, Jackson DG, Prevo R, Janes L, Velasco P et al (2001) Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat Med 7(2):192–198PubMedCrossRefGoogle Scholar
  24. 24.
    Mäkinen T, Jussila L, Veikkola T, Karpanen T, Kettunen MI, Pulkkanen KJ et al (2001) Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3. Nat Med 7(2):199–205PubMedCrossRefGoogle Scholar
  25. 25.
    Pavlakovic H, Von Schütz V, Rössler J, Koscielniak E, Havers W, Schweigerer L (2001) Quantification of angiogenesis stimulators in children with solid malignancies. Int J Cancer 92(5):756–760PubMedCrossRefGoogle Scholar
  26. 26.
    Zhou Q, Zhu Y, Deng Z, Long H, Zhang S, Chen X (2011) VEGF and EMMPRIN expression correlates with survival of patients with osteosarcoma. Surg Oncol 20(1):13–19PubMedCrossRefGoogle Scholar
  27. 27.
    Kreuter M, Paulussen M, Boeckeler J, Gerss J, Buerger H, Liebscher C et al (2006) Clinical significance of vascular endothelial growth factor-A expression in Ewing’s sarcoma. Eur J Cancer 42(12):1904–1911PubMedCrossRefGoogle Scholar
  28. 28.
    Mikulić D, Ilić I, Cepulić M, Orlić D, Giljević JS, Fattorini I et al (2004) Tumour angiogenesis. and outcome in osteosarcoma. Pediatr Hematol Oncol 21(7):611–619PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2012

Authors and Affiliations

  • Shishir Rastogi
    • 1
  • Ramakant Kumar
    • 1
  • Sukesh Rao Sankineani
    • 1
  • Kanniraj Marimuthu
    • 1
  • Laxman Rijal
    • 1
  • Shyam Prakash
    • 2
  • Divesh Jalan
    • 1
  • Shah Alam Khan
    • 1
  • Mehar C. Sharma
    • 3
  1. 1.Department of OrthopaedicsAll India Institute of Medical SciencesNew DelhiIndia
  2. 2.Human Nutrition Unit, Department of GastroenterologyAIIMSNew DelhiIndia
  3. 3.Department of PathologyAll India Institute of Medical SciencesNew DelhiIndia

Personalised recommendations